Back to results
US 2023/0265127 A1Published application
Stabilized soluble pre-fusion rsv f polypeptides
AssigneeJanssen Vaccines & Prevention B.V.
InventorsJohannes Petrus Maria LANGEDIJK, Anders Krarup
Life of this patent
Estimating the term…
Abstract
Described are stable pre-fusion respiratory syncitial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides and uses thereof for the prevention and/or treatment of RSV infection.
Claims20
-27. (canceled)
A recombinant pre-fusion respiratory syncytial virus (RSV) Fusion (F) polypeptide comprising:
- a mutation of the amino acid residue N/T at position 67 into I,
- a mutation of the amino acid residue S at position 215 into P, and
- a mutation of the amino acid residue D at position 486 into N,
- wherein the amino acid positions are given in reference to the sequence of RSV F protein from the A2 strain (SEQ ID NO:
- 1).
2 more elements
The method according to claim 45, wherein the adenoviral vector is an adenovirus serotype 26 (Ad26) vector.
Dependencies are inferred from the claim text.